Efficacy of psychostimulant drugs for amphetamine abuse or dependence

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 9, 2013, Pages

  Pérez Mañá, Clara ^a   Castells, Xavier ^b   Torrens, Marta ^c   Capellà, Dolors ^b   Farre, Magi ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF GIRONA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; CAFFEINE; COCAINE; DEXAMPHETAMINE; DIAMORPHINE; DOPAMINE; METHADONE; METHAMPHETAMINE; METHYLPHENIDATE; MODAFINIL; NORADRENALIN; PLACEBO; PSYCHOSTIMULANT AGENT; SEROTONIN; BENZHYDRYL DERIVATIVE; CENTRAL STIMULANT AGENT;

ADULT; AMPHETAMINE DEPENDENCE; ATTENTION DEFICIT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE BEHAVIORAL THERAPY; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DRUG CRAVING; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EUPHORIA; FEMALE; HAIR ANALYSIS; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMBRANE TRANSPORT; MENTAL DISEASE; NEUROTRANSMISSION; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT DROPOUT; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; SOCIAL PSYCHOLOGY; SUBSTITUTION THERAPY; SYSTEMATIC REVIEW; URINALYSIS; VISUAL ANALOG SCALE; DRUG ABUSE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); DRUG THERAPY;

AMPHETAMINE-RELATED DISORDERS; BENZHYDRYL COMPOUNDS; BUPROPION; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; HUMANS; METHYLPHENIDATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84898768492     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009695.pub2     Document Type: Review

References (81)

1. Anderson AL, Li SH, Biswas K, McSherry F, Holmes T, Iturriaga E, et al. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2012;120(1-3):135-41.
2. Das M, Santos D, Matheson T, Santos GM, Chu P, VittinghoffE, et al. Feasibility and acceptability of a phase II randomized pharmacologic intervention for methamphetamine dependence in high-risk men who have sex with men. AIDS 2010;24(7):991-1000.
3. Elkashef AM, Rawson RA, Anderson AL, Li SH, Holmes T, Smith EV, et al. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008;33(5):1162-70.
4. Galloway GP, Buscemi R, Coyle JR, Flower K, Siegrist JD, Fiske LA, et al. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther 2011;89(2):276-82.
5. Heinzerling KG, Swanson AN, Kim S, Cederblom L, Moe A, Ling W, Shoptaw S. Randomized, double-blind, placebo-controlled trial of modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend 2010;109(1-3):20-9.
6. Konstenius M, Jayaram-Lindström N, Beck O, Franck J. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend 2010;108(1-2):130-3.
7. Longo M, Wickes W, Smout M, Harrison S, Cahill S, White JM. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction 2010;105(1):146-54.
8. Mancino M. Modafinil for methamphetamine dependence. Clinicaltrials.gov (NCT00859573). Results published in April 15, 2011.
9. Shearer J, Darke S, Rodgers C, Slade T, van Beek I, Lewis J, et al. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction 2009;104(2):224-33.
10. Shoptaw S, Heinzerling KG, Rotheram-Fuller E, Steward T, Wang J, Swanson AN, et al. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend 2008;96(3):222-32.
11. Tiihonen J, Kuoppasalmi K, Föhr J, Tuomola P, Kuikanmäki O, Vorma H, et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 2007;164(1):160-2.
12. Brensilver M, Heinzerling KG, Swanson AN, Telesca D, Furst BA, Shoptaw SJ. Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment. Drug Alcohol Rev 2013;32(1):96-9.
13. Christian DR, Huber A, Brecht ML, McCann MJ, Marinelli-Casey P, Lord RH, et al. Methamphetamine Treatment Project, Galloway GP. Methamphetamine users entering treatment: characteristics of the methamphetamine treatment project sample. Subst Use Misuse 2007;42(14):2207-22.
14. Dean AC, London ED, Sugar CA, Kitchen CM, Swanson AN, Heinzerling KG, et al. Predicting adherence to treatment for methamphetamine dependence from neuropsychological and drug use variables. Drug Alcohol Depend 2009;105(1-2):48-55.
15. Hartz DT, Frederick-Osborne SL, Galloway GP. Craving predicts use during treatment for methamphetamine dependence: a prospective, repeated-measures, within-subject analysis. Drug Alcohol Depend 2001;63(3):269-76.
16. Marinelli-Casey P, Gonzales R, Hillhouse M, Ang A, Zweben J, Cohen J, et al. Methamphetamine Treatment Project Corporate Authors. Drug court treatment for methamphetamine dependence: treatment response and posttreatment outcomes. J Subst Abuse Treat 2008;34(2):242-8.
17. McCann DJ, Li SH. A novel, non binary evaluation of success and failure reveals bupropion efficacy versus methamphetamine dependence: reanalysis of a multisite trial. CNS Neurosci Ther 2012;18(5):414-8.
18. Shearer J, Wodak A, Mattick RP, Van Beek I, Lewis J, Hall W, Dolan K. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction 2001;96(9):1289-96.
19. Shearer J, Shanahan M, Darke S, Rodgers C, van Beek I, McKetin R, et al. A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence. Drug Alcohol Rev 2010;29(3):235-42.
20. Winchell C, Rappaport BA, Roca R, Rosebraugh CJ. Reanalysis of methamphetamine dependence treatment trial. CNS Neurosci Ther 2012;18(5):367-8.
21. Akhondzadeh. Slow-release methylphenidate in the treatment of methamphetamine dependence. International Clinical Trials Registry Platform.
22. Franck. Clinical trial of sustained release methylphenidate for attention-deficit-hyperactivity-disorder (ADHD) in adult criminal offenders with amphetamine addiction. EU Clinical Trials Register.
23. Galloway GP. A dose ranging study of modafinil for methamphetamine dependence. ClinicalTrials.gov.
24. Galloway GP. A randomized, placebo-controlled trial of modafinil for methamphetamine dependence. ClinicalTrials.gov.
25. Gorgon L. Phase 2, double-blind, placebo controlled trial of bupropion for methamphetamine dependence. ClinicalTrials.gov.
26. Heinzerling K. Study of medical treatment for methamphetamine addiction. ClinicalTrials.gov.
27. Ling W. Methylphenidate to treat methamphetamine dependence. ClinicalTrials.gov.
28. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. The Journal of Substance Abuse Treatment 2005;28(4):321-9.
29. Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, et al. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012;37:1192-203.
30. Boutrel B, Koob GF. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 2004;27:1181-94.
31. Brackins T, Brahm NC, Kissack JC. Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pract 2011;24(6):541-50.
32. Brensilver M, Heinzerling KG, Swanson AN, Shoptaw S. A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: suggested guidelines for treatment discontinuation/augmentation. Drug Alcohol Depend 2012;125(1-2):169-72.
33. Castells X, Casas M, Vidal X, Bosch R, Roncero C, Ramos-Quiroga JA, et al. Efficacy of central nervous system stimulant treatment for cocaine dependence: a systematic review and meta-analysis of randomized controlled clinical trials. Addiction 2007;102(12):1871-87.
34. Castells X, Casas M, Pérez-Mañá C, Roncero C, Vidal X, Capellà D. Efficacy of Psychostimulant Drugs for Cocaine Dependence. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD007380.pub3]
35. Chang L, Alicata D, Ernst T, Volkow N. Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 2007;102:16-32.
36. Chen H, Wu J, Zhang J, Hashimoto K. Recent topics on pharmacotherapy for amphetamine-type stimulants abuse and dependence. Current Drug Abuse Reviews 2010;3(4):222-38.
37. Colfax G, Santos GM, Chu P, VittinghoffE, Pluddemann A, Kumar S, et al. Amphetamine-group substances and HIV. Lancet 2010;376:458-74.
38. De La Garza R 2nd, Zorick T, London ED, Newton TF. Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug and Alcohol Dependence 2010;106(2-3):173-80.
39. Degenhardt L, Bruno R, Topp L. Is ecstasy a drug of dependence?. Drug and Alcohol Dependence 2010;107:1-10.
40. Drobes DJ, Thomas SE. Assessing craving for alcohol. Alcohol Research & Health 1999;23:179-86.
41. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association, 2000.
42. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. British Medical Journal 1997;315:629-34.
43. Eisenberg MJ, Filion KB, Yavin D, Bélisle P, Mottillo S, Joseph L, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomised controlled trials. Canadian Medical Association Journal 2008;179(2):135-44.
44. Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J. Pharmacotherapy of methamphetamine addiction: an update. Substance Abuse 2008;29(3):31-49.
45. Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Mooney LJ, Rawson R, Methamphetamine Treatment Project Corporate Authors. Depression among methamphetamine users: association with outcomes from the Methamphetamine Treatment Project at 3-year follow-up. The Journal of Nervous and Mental Disease 2009;197(4):225-31.
46. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson RA, Methamphetamine Treatment Project Corporate Authors. Psychopathology in methamphetamine-dependent adults 3 years after treatment. Drug and Alcohol Reviews 2010;29:12-20.
47. Guy W. In: Clinical Global Impressions: ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute for Mental Health, 1976.
48. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32:50-5.
49. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
50. Herin DV, Rush CR, Grabowski J. Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies. Annals of the New York Academy of Sciences 2010;1178:76-100.
51. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
52. Howell LL, Kimmel HL. Monoamine transporters and psychostimulant addiction. Biochemical Pharmacology 2008;75(1):196-217.
53. Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL. Pharmacological approaches to methamphetamine dependence: a focused review. Bristish Journal of Clinical Pharmacology 2010;69(6):578-92.
54. King GR, Ellinwood EH. Amphetamines and other stimulants. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG editor(s). Substance Abuse. A Comprehensive Textbook. 4th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2005:207-22.
55. Kirkpatrick MG, Gunderson EW, Perez AY, Haney M, Foltin RW, Hart CL. A direct comparison of the behavioral and physiological effects of methamphetamine and 3, 4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2012;219:109-22.
56. Kirkpatrick MG, Gunderson EW, Johanson CE, Levin FR, Foltin RW, Hart CL. Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans. Addiction 2012;107(4):783-91. [DOI: 10.1111/j.1360-0443.2011.03706.x]
57. Knapp WP, Soares BG, Farrel M, Lima MS. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD003023.pub2]
58. Koob GF. Neurobiological substrates for the dark side of compulsivity in addiction. Neuropsychopharmacology 2009;56(1):18-31.
59. Kosman ME, Unna DR. Effects of chronic administration of the amphetamines and other stimulants on behavior. Clinical Pharmacology & Therapeutics 1968;9:240-54.
60. Lee NK, Rawson RA. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug and Alcohol Reviews 2008;27(3):309-17.
61. Makris AP, Rush CR, Frederich RC, Taylor AC, Kelly TH. Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults. Experimental and Clinical Psychopharmacology 2007;15(2):123-33.
62. Martin WR, Sloan JW, Sapira JD, Jasinski DR. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clinical Pharmacology & Therapeutics 1971;12(2):245-58.
63. McGregor C, Srisurapanont M, Mitchell A, Wickes W, White JM. Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. The Journal of Substance Abuse Treatment 2008;35(3):334-42.
64. Moeller FG, Schmitz JM, Herin D, Kjome KL. Use of stimulants to treat cocaine and methamphetamine abuse. Current Psychiatry Report 2008;10(5):385-91.
65. Newton TF, De La Garza R, Kalechstein AD, Nestor L. Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects. Pharmacology Biochemistry and Behaviour 2005;82(1):90-7.
66. Newton TF, Roache JD, De la Garza R 2nd, Fong T, Wallace CL, Li SH, et al. Bupropion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 2006;31(7):1537-44.
67. Methamphetamine: Abuse and Addiction. NIDA Research Report 2006; Vol. NIH Publication Number 06-4210.
68. Pérez-Mañá C, Castells X, Vidal X, Casas M, Capellà D. Efficacy of indirect dopamine agonists for psychostimulant dependence: a systematic review and meta-analysis of randomized controlled trials. The Journal of Substance Abuse Treatment 2011;40(2):109-22.
69. Robinson JB. Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl. Biochemical Pharmacology 1985;34(23):4105-8.
70. Rossetti ZL, Hmaidan Y, Gessa GL. Marked inhibition of mesolimbic dopamine release: a common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. European Journal of Pharmacology 1992;221:227-34.
71. Salo R, Flower K, Kielstein A, Leamon MH, Nordahl TE, Galloway GP. Psychiatric comorbidity in methamphetamine dependence. Psychiatry Research 2011;186(2-3):356-61.
72. Shearer J. Psychosocial approaches to psychostimulant dependence: a systematic review. The Journal of Substance Abuse Treatment 2007;32(1):41-52.
73. Shearer J. The principles of agonist pharmacotherapy for psychostimulant dependence. Drug and Alcohol Reviews 2008;27(3):301-8.
74. Shoptaw SJ, Kao U, Heinzerling K, Ling W. Treatment for amphetamine withdrawal. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD003021.pub2]
75. Somoza E, Dyrenforth S, Goldsmith J, Mezinskis J, Cohen M. In search of a universal drug craving scale. Proceedings of the Annual Meeting of the American Psychiatric Association, Miami, Florida. 1995.
76. Srisurapanont M, Jarusuraisin N, Kittirattanapaiboon P. Treatment for amphetamine dependence and abuse. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD003022]
77. UNODC. World Drug Report 2012. United Nations Publication, Sales No. E.12.XI.1 2012.
78. Patterns and consequences of the use of amphetamine-type stimulants. http://www.who.int/hiv/pub/idu/ats_brief1.pdf. Accessed 1 July 2011.
79. Wilens TE. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatric Clinics of North America 2004;27(2):283-301.
80. Xi ZX, Gardner EL. Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Current Drug Abuse Reviews 2008;1(3):303-27.
81. Zahniser NR, Sorkin A. Trafficking of dopamine transporters in psychostimulant actions. Seminars in Cell & Developmental Biology 2009;20(4):411-7.